Chef is leaving popular Thai restaurant in KC, but it won't close, owners say
Popular Kansas City restaurant Waldo Thai is going through some changes.
After the general manager said Friday morning that the spot would close, 'at least for a little bit,' the restaurant's chief financial officer said that evening that it would remain open at 8431 Wornall Road under different management.
Ted Liberda, who helped to open the spot in 2018, told The Star on Friday morning that he and his wife, Pam Liberda, are leaving the concept May 17 to focus on their other two restaurants: Buck Tui BBQ at 6737 W. 75th St. in Overland Park and MuNi at 316 Delaware St.
'It's gonna be operating under new management, possibly, but it's gonna take some time for the turnaround, so it'll be closed for at least a little bit,' he said of Waldo Thai on Friday morning.
Later Friday, however, Scott Keithly, the restaurant's chief financial officer, said it will remain open.
'(The Liberdas) made the decision this week that they were gonna move on, but we never told them we were gonna close the place,' Keithly said. 'We're just gonna hire a new chef and keep operating.'
Ted said they're looking forward to another restaurant project. He can't announce when, where or what it will be just yet, but he did say it will be in a 'prominent location' on the Missouri side.
The Liberdas opened the restaurant in 2018 after Pam told her husband she wanted to open a restaurant that served the same dishes she grew up enjoying, specifically the Lanna Thai cuisine from Northern Thailand.
Such menu items include gaeng hung lei — a curry with braised pork belly, palm sugar and spices — and nam prik orng, which has pork-based relish, tomatoes, serrano peppers, and fermented soy beans and shrimp paste.
While it's sad for the Liberdas to leave Waldo Thai, Ted said they're excited for what's to come.
'Heartfelt thank you to everyone who's supported us throughout the years … So many wonderful memories and relationships in that place,' Ted said. 'We look forward to the next chapter of our life.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
'High risk': The Star's $167m credit to money launderer
The Star was willing to offer millions in gambling credit to a known money launderer and wrote falsified letters to enable overseas bank transfers from unknown individuals. These details and many more have been exposed as financial watchdog AUSTRAC pursues the embattled casino giant in the Federal Court. The Star made "innumerable contraventions" of Australian anti-money laundering laws through its conduct, including a willingness to do business with 117 high-risk customers, barrister Daniel Tynan told a Federal Court hearing on Thursday. The casino has admitted that 70 of these customers - who were junket funders, operators or players - each posed a high money laundering risk. "They would have the opportunity to gamble that money, get the returns, wash it, do it again," Mr Tynan told Justice Cameron Moore. One of these customers, Suncity junket operator Alvin Chau, was provided with credit of up to $266.67 million. Chau funded at least 3690 junket programs at The Star's Sydney casino, bringing in a turnover of about $12.6 billion. Despite media reports linking him to overseas crime syndicates, The Star continued to engage with the Suncity head, Mr Tynan said. It was only after Chau was arrested by Macau police and hit with a number of charges - including money laundering - that the casino stopped dealing with him, the court has heard. Another customer was given almost $167 million in credit despite The Star knowing from at least 2014 that he had been involved in alleged money laundering, Mr Tynan said. The casino also facilitated high-risk transactions from 1221 customers who transferred money in and out through channels that obscured their identity, the court was told. Staff at EEIS, a Macau-based subsidiary of The Star, wrote up falsified letters for local customers wanting to send funds through the Bank of China directly to the casino, Mr Tynan continued. These letters contained false claims about the source of the funds being deposited, the barrister said. Almost $990 million in deposits were made through The Star's hotel debit cards, allowing gamblers to transfer money directly to the casino without going through an Australian bank. The cards also allowed gamblers in countries like China with restrictions on gambling to disguise their transactions by claiming they were for other purposes like hotel accommodation, Justice Moore was told. The Star advanced money to customers who complained about the 24 to 48-hour waiting period before funds hit their accounts. Individuals could also withdraw cash directly, Mr Tynan said. "This is coming in anonymously, taken out in cash - it can be used for anything." AUSTRAC is seeking $400 million in penalties over the breaches while the casino has argued it can only pay $100 million without being pushed into administration. In April, the failing casino business received a $300 million rescue package from US gaming giant Bally's Corporation. The hearing continues on Friday.
Business Journals
5 days ago
- Business Journals
Ted Williams
Architects & Engineering | Career Update Ted Williams, McKim & Creed After serving as President of Landmark Science & Engineering (Newark, Del.), Ted Williams transitioned to a key leadership role as Vice President and Regional Manager at McKim & Creed, following the firm's acquisition in May 2025. In this new role, Ted will oversee McKim & Creed's Mid-Atlantic growth. Ted's expertise includes 48 years of experience performing comprehensive civil engineering design and project management for various land development, transportation, and construction projects.
Yahoo
5 days ago
- Yahoo
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
BEIJING & NANJING, China, June 04, 2025--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("NJCTTQ") announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About NTB003 Injection NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody co-developed by Biocytogen and Nanjing Chia Tai Tianqing. Antibody discovery and optimization were completed by Biocytogen using its proprietary RenMab™ fully human antibody discovery platform, while Nanjing Chia Tai Tianqing was responsible for CMC process development, GLP-compliant toxicology studies, and IND application. Compared with first-generation approved anti-IGF-1R therapeutics, NTB003 demonstrates enhanced molecular affinity, improved druggability, and an extended half-life. In vitro studies have shown that NTB003 exerts potent signal-blocking activity and effectively inhibits the release of hyaluronic acid (HA), indicating strong potential for further clinical development. Clinical studies of teprotumumab and other investigational anti-IGF-1R biologics have demonstrated that targeting IGF-1R can deliver significant clinical benefits. These agents have shown rapid onset of therapeutic response and favorable outcomes in reducing proptosis and diplopia, improving quality of life, and lowering clinical activity scores in patients with TED. Nanjing Chia Tai Tianqing will lead the clinical development and commercialization of NTB003 in China, aiming to provide an improved therapeutic option for Chinese TED patients. Biocytogen will be responsible for the global out-licensing of the product outside China. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Contacts Biocytogen Contacts Antibody assets and platforms: BD-Licensing@ Media: pr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
